Understanding how RBM10 loss affects immune response in lung cancer
Official title: Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11077772 · Data updated 2026-11-12
This study is looking at how a gene called RBM10 affects non-small cell lung cancer with KRAS mutations, focusing on how its loss can make the cancer harder to treat with immunotherapy, and aims to find new ways to help improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 2, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $370,575 |
| NIH project number | 5R01CA272570-03 |
| Project ID | NIH-11077772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KRAS-mutant non-small cell lung cancer, particularly those with RBM10 loss.
✕Less likely to help
Patients with non-small cell lung cancer who do not have KRAS mutations or RBM10 loss may not benefit from this research.
What this research studies
This research investigates the role of RBM10, a gene involved in RNA splicing, in non-small cell lung cancer (NSCLC) with KRAS mutations. It aims to understand how the loss of RBM10 leads to genomic instability and immune evasion, which can affect the effectiveness of immunotherapy treatments. The study will explore the mechanisms behind this process, including the accumulation of specific RNA structures and their impact on immune cell behavior in the tumor environment. By using advanced laboratory techniques, the research seeks to identify potential new therapeutic targets to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRAS-mutant lung cancer by enhancing the immune response against tumors.
How similar studies have gone: Previous research has shown promising results in targeting immune evasion mechanisms in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.